Future studies will be addressed to verify whether GAS5 and miR-126-3p may be potential early/predictive circulating biomarkers in at high-risk patients (i.e. patients with cirrhosis and/or HBV, HCV chronic hepatitis). This evidence concerns the gene GAS5 and Cirrhosis.